APOE and early-onset autosomal dominant Alzheimer disease: Previous studies have implicated HMGCR in Alzheimer’s disease (AD) as a genetic modifier of risk and cognitive decline, comparable to APOE, the main cholesterol transporter in the brain [5, 26].